Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.03+0.07 (+7.29%)
Close on Nov 18, 2026Market cap $28.59MP/E –Yield –
Inmune Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Inmune Bio's operating income for the twelve months ending Jun 30, 2026 was -$20.20M. For fiscal 2025 it was -$47.38M. The highest annual figure on record is -$981.48K in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$47.38M | – |
| FY2024 | Dec 31, 2024 | -$42.64M | – |
| FY2023 | Dec 31, 2023 | -$29.74M | – |
| FY2022 | Dec 31, 2022 | -$25.95M | – |
| FY2021 | Dec 31, 2021 | -$29.15M | – |
| FY2020 | Dec 31, 2020 | -$12.23M | – |
| FY2019 | Dec 31, 2019 | -$7.76M | – |
| FY2018 | Dec 31, 2018 | -$12.44M | – |
| FY2017 | Dec 31, 2017 | -$981.48K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.48M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.81M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.87M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.02M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.64M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.44M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.03M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.55M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.82M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.11M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.09M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.33M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.08M | – |
| Q2 FY2019 | Jun 30, 2019 | -$428.42K | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.91M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.88M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.54M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.17M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.85M | – |
See a number that looks wrong?